<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="about.html">About</a>
            <a href="index.html">Index</a>
        </div>
    <div class="header"><h3>CORONA</h3></div><p><span class="main">"Rosuvastatin in Older Patients with Systolic Heart Failure". The New England Journal of Medicine. 2007. 357(22):2248-2261. PubMed </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/CORONA>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa0706201>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents
 </span></p><p><span class="main">1. Clinical Question
2. Bottom Line
3. Major Points
4. Guidelines
5. Design
6. Population
   6.1 Inclusion Criteria
   6.2 Exclusion Criteria
   6.3 Baseline Characteristics
7. Interventions
8. Outcomes
   8.1 Primary Outcome
   8.2 Secondary Outcomes
9. Criticisms
10. Funding
11. Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">In older patients with systolic heart failure, does the addition of rosuvastatin to standard heart failure therapy affect cardiovascular outcomes?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">In older patients with systolic heart failure, rosuvastatin did not reduce the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke despite improving lipid profiles.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">This study assessed the impact of statin therapy on cardiovascular outcomes in a population with systolic heart failure, where acute coronary events are less common. The results indicated no reductions in primary composite outcome or total mortality but did show a reduction in cardiovascular hospitalizations.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">As of the most recent guidelines, specific recommendations regarding statin therapy in systolic heart failure have not been universally established.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Multicenter, double-blind, randomized, placebo-controlled trial
- N=5,011 patients with systolic heart failure, at least 60 years old
- Rosuvastatin (10 mg daily) vs. placebo
- Median follow-up: 32.8 months
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Inclusion Criteria
 </span></p><p><span class="main">- Age ≥60 years
- NYHA class II, III, or IV ischemic systolic heart failure
- Ejection fraction ≤40% (≤35% if NYHA class II)
 </span></p><p><span class="main">Exclusion Criteria
 </span></p><p><span class="main">- Previous statin-induced myopathy
- Decompensated heart failure
- Recent myocardial infarction, unstable angina, or stroke
- Recent or planned revascularization or device implantation
- Significant noncardiac comorbidity
 </span></p><p><span class="main">Baseline Characteristics
 </span></p><p><span class="main">- Well-matched between groups
- Mean age 73 years
- High rates of comorbid conditions such as hypertension and diabetes
- Majority on comprehensive heart failure medication regimens
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Rosuvastatin 10 mg or matching placebo, once daily
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Primary Outcome
 </span></p><p><span class="main">- No significant reduction in the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke with rosuvastatin
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- No significant reduction in all-cause mortality
- Fewer hospitalizations for cardiovascular causes with rosuvastatin
- No impact on NYHA functional class or patient well-being
- Rosuvastatin demonstrated a favorable safety profile
 </span></p><h2><span class="labels">Criticisms</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Patients were typically on extensive background heart failure therapies, which might have influenced the lack of observed benefit.
- The population may not represent all patients with systolic heart failure, such as those with nonischemic heart failure or those with a preserved ejection fraction.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Supported by AstraZeneca.
- Multiple authors reported personal fees from AstraZeneca and other disclosures.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Full article on The New England Journal of Medicine's website. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>